Copyright
©The Author(s) 2019.
World J Clin Infect Dis. May 21, 2019; 9(1): 1-10
Published online May 21, 2019. doi: 10.5495/wjcid.v9.i1.1
Published online May 21, 2019. doi: 10.5495/wjcid.v9.i1.1
Infections | Antibiotic Treatment | |
Skin and soft tissue infections (SSTIs) | ||
Uncomplicated SSTIs | Clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), a tetracycline (doxycycline or minocycline) (A-II), linezolid | |
Complicated SSTIs | IV Vancomycin, Linezolid (oral or IV 600 mg twice daily), Daptomycin (4 mg/kg/dose IV once daily), Telavancin (10 mg/kg/dose IV once daily), Clindamycin (600 mg IV or PO 3 times a day) | |
Recurrent SSTIs | Nasal decolonization - mupirocin twice daily +/- topical body decolonization - skin antiseptic solution (e.g. chlorhexidine) or dilute bleach baths. | |
Bacteraemia and infective endocarditis | ||
Native valve endocarditis | Vancomycin; Daptomycin (6 mg/kg/dose IV once daily) | |
Prosthetic valve endocarditis | Vancomycin + Rifampin (300 mg PO/IV every 8 hour) followed by Gentamicin (1 mg/kg/dose IV every 8 hour) | |
Pneumonia | ||
Community acquired, or healthcare associated | IV vancomycin or linezolid (600 mg PO/IV twice daily) or clindamycin (600 mg PO/IV 3 times daily) | |
Bone and joint infections | ||
Osteomyelitis or Septic arthritis | Vancomycin; Daptomycin (6 mg/kg/dose IV once daily); TMP-SMX [4 mg/kg/dose (TMP component) twice daily] + Rifampin (600 mg once daily) | |
Device-related osteo-articular infections (early onset < 2 mo - prosthetic joint infections) | Vancomycin or Daptomycin (6 mg/kg/dose IV once daily) + Rifampin (600 mg once daily) followed by; Rifampin + fluoroquinolone / TMP- SMX / tetracycline / clindamycin | |
Device-related osteo-articular infections (early onset < 2 mo - spinal implant infections) | Initial parenteral therapy + Rifampin followed by prolonged oral therapy | |
CNS infections | ||
Meningitis, Brain abscess, subdural empyema, spinal epidural abscess, Septic Thrombosis of Cavernous or Dural Venous Sinus | IV Vancomycin +/- Rifampin; OR; Linezolid 600 mg PO/IV twice daily or TMP-SMX 5 mg/kg/dose IV every 8-12 hour |
- Citation: Kashyap R, Shah A, Dutt T, Wieruszewski PM, Ahdal J, Jain R. Treatments and limitations for methicillin-resistant Staphylococcus aureus: A review of current literature. World J Clin Infect Dis 2019; 9(1): 1-10
- URL: https://www.wjgnet.com/2220-3176/full/v9/i1/1.htm
- DOI: https://dx.doi.org/10.5495/wjcid.v9.i1.1